Fractyl Health (NASDAQ:GUTS) Posts Earnings Results, Misses Estimates By $0.02 EPS

Fractyl Health (NASDAQ:GUTS) released its earnings results on Monday. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02), FiscalAI reports.

Fractyl Health Stock Down 3.5%

Shares of Fractyl Health stock traded down $0.02 during midday trading on Monday, hitting $0.68. The company had a trading volume of 1,484,849 shares, compared to its average volume of 3,386,296. The company has a debt-to-equity ratio of 1.41, a quick ratio of 4.28 and a current ratio of 4.28. The stock has a market capitalization of $107.09 million, a P/E ratio of -0.52 and a beta of 2.32. The company has a 50 day moving average of $0.77 and a 200 day moving average of $0.71. Fractyl Health has a 52-week low of $0.38 and a 52-week high of $2.44.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on GUTS shares. Craig Hallum initiated coverage on Fractyl Health in a research note on Wednesday, July 1st. They issued a “buy” rating and a $4.00 price target on the stock. Weiss Ratings lowered Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday. Wall Street Zen upgraded shares of Fractyl Health from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a research report on Thursday, June 4th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Fractyl Health presently has a consensus rating of “Moderate Buy” and an average target price of $5.12.

Insider Buying and Selling

In related news, Director Ian Sheffield bought 35,000 shares of the company’s stock in a transaction on Wednesday, June 10th. The shares were acquired at an average cost of $0.73 per share, with a total value of $25,550.00. Following the completion of the acquisition, the director owned 35,000 shares of the company’s stock, valued at $25,550. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director William Bradley bought 68,493 shares of the business’s stock in a transaction dated Wednesday, June 10th. The stock was bought at an average cost of $0.73 per share, for a total transaction of $49,999.89. Following the completion of the purchase, the director owned 84,622 shares of the company’s stock, valued at approximately $61,774.06. The trade was a 424.66% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have purchased 171,493 shares of company stock valued at $127,150. 8.52% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Fractyl Health

Several large investors have recently modified their holdings of the stock. Nantahala Capital Management LLC bought a new stake in Fractyl Health during the 3rd quarter valued at about $19,298,000. Alyeska Investment Group L.P. bought a new position in shares of Fractyl Health in the third quarter worth approximately $8,981,000. Woodline Partners LP lifted its stake in shares of Fractyl Health by 821.1% in the third quarter. Woodline Partners LP now owns 5,506,534 shares of the company’s stock worth $8,755,000 after buying an additional 4,908,693 shares in the last quarter. General Catalyst Group Management LLC purchased a new stake in shares of Fractyl Health during the second quarter valued at approximately $7,912,000. Finally, Marshall Wace LLP grew its holdings in shares of Fractyl Health by 234.9% during the fourth quarter. Marshall Wace LLP now owns 5,926,745 shares of the company’s stock valued at $13,039,000 after buying an additional 4,156,969 shares during the last quarter.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.